Haemonetics Corporation
103.16USD
+0.3200 (+0.31%)
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | — | 1.3B | 1.4B | 1.3B | 1.4B | 1.5B |
| Q1 | 261.5M | 311.3M | 336.2M | 321.4M | 339.4M | — |
| Q2 | 297.5M | 318.2M | 345.5M | 327.3M | 345.0M | — |
| Q3 | 305.3M | 336.3M | 348.5M | 339.0M | 356.7M | — |
| Q4 | — | 343.3M* | 330.6M* | 346.4M* | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | — | 2.29 | 3.31 | 2.05 | 5.30 | 5.74 |
| Q1 | .380 | .800 | .740 | .700 | .720 | — |
| Q2 | .640 | .480 | .660 | .810 | 1.29 | — |
| Q3 | .640 | .610 | .740 | .950 | 1.35 | — |
| Q4 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .396* |
| 1.14* |
| -.425* |
| — |
| — |